课题基金 / 基金详情

Program 35: Melanoma

Program 35: Melanoma
项目 35:黑色素瘤
批准号:
10062943
负责人:
FRANK S HODI
金额:
$7.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-03-10 至 2021-11-30

项目摘要

项目成果

FRANK S HODI的其他基金

相似基金

相关文献

中文摘要
翻译
黑色素瘤的程序
英文摘要
Melanoma Program Project Summary / Abstract Preclinical and clinical researchers in the Melanoma Program advance the Program mission to study all aspects of melanoma and translate the findings into actionable diagnostic, preventative, and therapeutic opportunities that will improve the lives of patients and contribute to our understanding of the disease. The Specific Aims of the Program are: 1) To understand the molecular pathogenesis of melanoma, including genomics, epigenomics, metabolomics, and utilize this information for optimal therapeutic targeting; 2) To understand tumor-host interactions and utilize this information to optimize therapeutic strategies that target the tumor microenvironment; and 3) To understand the external environmental factors that modulate melanoma risk and carcinogenesis, as well as the human behaviors associated with melanoma formation. The program has 44 members, representing six DF/HCC institutions and seven academic departments. In 2014 peer- reviewed grant funding attributed to the Program was $3.7 million in total costs from the NCI and $1.6 million from other sponsors. During the current funding period, Melanoma Program members published 873 cancer- relevant papers. Of these 30% were inter-institutional, 21% were intra-programmatic, and 39% were inter- programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter-programmatic collaborations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
3D Models of Immunotherapy
  • 批准号:
    9283025
  • 项目类别:
  • 资助金额:
    $57.44万
  • 财政年份:
    2017
  • 负责人:
    FRANK S HODI
  • 依托单位:
3D Models of Immunotherapy
  • 批准号:
    9896778
  • 项目类别:
  • 资助金额:
    $55.68万
  • 财政年份:
    2017
  • 负责人:
    FRANK S HODI
  • 依托单位:
Cancer Immune Monitoring and Analysis Center
  • 批准号:
    10730296
  • 项目类别:
  • 资助金额:
    $197.39万
  • 财政年份:
    2017
  • 负责人:
    FRANK S HODI
  • 依托单位:
Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
  • 批准号:
    8081790
  • 项目类别:
  • 资助金额:
    $32.32万
  • 财政年份:
    2010
  • 负责人:
    FRANK S HODI
  • 依托单位:
海外基金